Results 71 to 80 of about 12,338 (219)
A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside
Interdisciplinary Medicine, EarlyView.This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione +2 more
wiley +1 more source
Haematologica, 2015 Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus +15 more
doaj +1 more source
Zhongguo aizheng zazhi, 2016 Background and purpose: Although bortezomib has become one of the major therapeutic agents against newly diagnosed or relapsed multiple myeloma (MM), there are some patients who become resistant to bortezomib and then relapse, emerging as a major ...
王莹莹, 钟 瑶, 俞夜花
doaj
BMC Cancer, 2012 Background Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory.
Wang Cun +12 more
doaj +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu +5 more
wiley +1 more source
Bortezomib induces autophagy in HCC.
, 2013 A, dose-dependent effects of bortezomib-induced autophagy. HCC cells were treated with bortezomib at the indicated concentrations for 24 hours. Cell lysates were prepared for immunoblotting of microtubule-associated protein 1 light chain 3 (LC3). B, time-
Chung-Wai Shiau (285430) +6 more
core +1 more source
Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria
Journal of Global Oncology, 2017 Purpose: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM).
Kaladada I. Korubo +3 more
doaj +1 more source
Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa +2 more
wiley +1 more source
Haematologica, 2012 Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment.
Silvia C. W. Ling +11 more
doaj +1 more source
Macromolecular Rapid Communications, EarlyView.Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley +1 more source